Compare BMHL & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMHL | BDSX |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | Hong Kong | United States |
| Employees | 9 | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.4M | 153.3M |
| IPO Year | N/A | 2020 |
| Metric | BMHL | BDSX |
|---|---|---|
| Price | $5.91 | $19.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 3.5K | ★ 91.9K |
| Earning Date | 06-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | N/A | $25.26 |
| Revenue Next Year | N/A | $19.15 |
| P/E Ratio | $66.66 | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $2.72 | $0.30 |
| 52 Week High | $6.35 | $24.92 |
| Indicator | BMHL | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 64.03 | 51.12 |
| Support Level | $5.58 | $18.91 |
| Resistance Level | $6.35 | $20.21 |
| Average True Range (ATR) | 0.31 | 2.15 |
| MACD | -0.07 | -0.34 |
| Stochastic Oscillator | 82.53 | 15.65 |
Bluemount Holdings Ltd through its operating subsidiaries, is a Hong Kong-based consulting and advisory, financial services, and luxury timepiece trading provider. The Company provides consulting and advisory services on business development strategies, including seeking suitable transaction projects for business development or diversification and suitable business partners or investors for fund-raising projects. Its services are centered around three core offerings: Business Transformation, Strategy, and Transactions. The Company also sources, buys, and sells brand-new luxury branded timepieces. It operates through two reportable segments: security-related services and asset management, and trading of timepieces, with the trading of timepieces generating maximum revenue.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.